• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

27.53 -1.40 (-4.84%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 997,973
Open 28.89
Bid (Size) 27.55 (100)
Ask (Size) 32.00 (100)
Prev. Close 28.93
Today's Range 27.46 - 28.89
52wk Range 22.10 - 45.14
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses ↗
September 22, 2026
Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained... 
Via MarketBeat
Tuesday's pre-market session: top gainers and losers ↗
September 22, 2026
Via Chartmill

Performance

52-Week Range 39.0% below 52-week high
27.53
22.1052W Low 45.1452W High
1 Week 8.3% below 1-week high
27.461W Low 30.021W High

Celldex Therapeutics, Inc. - Common Stock (CLDX) traded between $22.10 and $45.14 over the past 52 weeks and last traded at $27.53, 39.0% below its 52-week high. Over the past week it ranged between $27.46 and $30.02.

Past 12 Months
-6.5%
-28.9%
-22.1%
-20.3%
+1.9%
+3.7%
1W -$1.90
1M -$11.18
3M -$7.82
6M -$7.02
YTD +$0.52
1Y +$0.98

CLDX was +3.7% over the past year, -20.3% over six months, +1.9% year to date, -6.5% in the last week.

12 Months vs Market
CLDX
+3.7%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months CLDX returned +3.7% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.74× 3-mo avg
Today 997,973 3-mo avg 1.4M
1W
1.1M
1M
2.3M
3M
1.4M
6M
1.2M
YTD
1.1M
1Y
1.0M

CLDX most recently traded 997,973 shares against a 3-month average daily volume of 1.4M.

More News

Read More
News headline image
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
September 22, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics (NASDAQ:CLDX) Q2 EPS Beat Overshadowed by Revenue Miss and Prurigo Nodularis Discontinuation ↗
August 06, 2026
Via Chartmill
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup ↗
May 14, 2026
Via Chartmill
News headline image
Celldex to Present at Upcoming Investor Conference
September 08, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
August 06, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss ↗
July 22, 2026
Via MarketBeat
News headline image
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
July 21, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Planned Transition of Chief Financial Officer
July 15, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
June 19, 2026
Via InvestorPlace
News headline image
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 14, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 14, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
June 10, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
May 19, 2026
Via Chartmill
News headline image
Celldex Reports First Quarter Financial Results and Provides Corporate Update
May 07, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Upcoming Investor Conference
April 13, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 06, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
April 01, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Proposed Public Offering of Common Stock
April 01, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
March 21, 2026
Via The Motley Fool

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
What is the current price of Celldex Therapeutics, Inc. - Common Stock?
The current price of Celldex Therapeutics, Inc. - Common Stock is 27.53
When was Celldex Therapeutics, Inc. - Common Stock last traded?
The last trade of Celldex Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.83B
How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap